Daily IPO Digest
Daily Digest — September 22, 2026
Published
Not financial or investment advice, and not a solicitation to buy or sell any security or to use our service. This is AI-assisted analysis of public SEC filings, provided for informational purposes only.
Figures are drawn from those filings and checked against them; any interpretation, conclusion or forecast is our analytical opinion rather than a statement of fact. We do not intend to defame any person or entity.
It is generated by an automated pipeline with no human review and will likely contain factual errors, interpretive errors, and errors of omission that misrepresent the business or the offering — none of them intentional. Do not rely on it as the sole basis for any investment decision. Always do your own research.
Just Filed
Iambic Therapeutics
No ticker yet · Initial S-1 · oncology / AI drug discovery · terms not yet set · Nasdaq (proposed)
Iambic Therapeutics, founded in 2019, is an AI-assisted drug discovery company targeting oncology — and the S-1 makes clear that however the platform is pitched, it will trade as a Phase 1 biotech. The company has raised $461.8 million since inception across equity and collaboration deals, and the partnership revenue story is the most concrete validation it has: collaboration revenue jumped from $3.9 million in the first half of 2025 to $12.8 million in the first half of 2026, backed by three named pharma partners. The lead program, IAM1363, has dosed 68 subjects at the go-forward dose in a Phase 1/1b trial, with 4 Grade 3 adverse events observed in monotherapy and no efficacy data yet disclosed. Two additional programs are in preclinical development.
The burn is steep: R&D expense in H1 2026 reached $57.1 million, up from $32.9 million in H1 2025, and the net loss for the first half of 2026 was $50.1 million against a $245.3 million accumulated deficit. Cash on hand sits at $207.9 million — enough runway to reach IND filings planned for two additional candidates and into early clinical data on IAM1363, but the IPO proceeds will determine how much cushion follows. The company carries $66.5 million in convertible notes alongside the preferred stock that will convert at IPO. The first efficacy signal from IAM1363 — which the company has signaled could support a registrational trial as early as 2027 — is the data point that will determine whether the post-IPO multiple holds, not the AI platform story.
Silicon Valley Acquisition Corp. II
No ticker yet · Initial S-1 · SPAC · filed to raise up to $220 million in trust (up to $253 million with greenshoe) · Nasdaq (proposed)
Silicon Valley Acquisition Corp. II is a blank-check company targeting technology, fintech, deep tech, and adjacent sectors, filing to raise up to $220 million in trust at $10.00 per unit. The sponsor's prior vehicle history is visible in the prospectus and worth reading carefully. The first Silicon Valley Acquisition Corp. (SVAQ) has a pending EigenQ business combination at a $3 billion pro forma enterprise value, with SVAQ units currently trading at $10.11 — a thin premium to trust. The more pointed data point comes from Columbus Circle Capital Corp. I (CCCM), another prior vehicle affiliated with the sponsor network: 93.7% of public shareholders redeemed at the combination vote at $10.21 per share, requiring a substantial PIPE raise to complete the ProCap transaction.
The standard SPAC economics apply here: the sponsor paid $25,000 for founder shares that will represent 25% of post-IPO equity, and deferred underwriting of $8.8 million sits payable on deal close. The combination deadline is 720 days from closing. The filing discloses that at maximum redemption, net tangible book value per share falls to $0.16 — a $9.84 dilution versus the offer price. Terms are not yet final.
Sources
Regulatory filings
- SEC filings